Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 8.73% | 147.66 | 0.0% | $994.17m | |
| AMGN | Amgen, Inc. | 0.87% | 255.26 | 1.5% | $856.48m | |
| GILD | Gilead Sciences, Inc. | 0.51% | 64.80 | 1.0% | $543.24m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 1.51% | 273.73 | 1.9% | $497.98m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.37% | 692.80 | 2.6% | $444.80m | |
| ILMN | Illumina, Inc. | 5.95% | 258.06 | 3.3% | $337.13m | |
| NVAX | Novavax, Inc. | 17.46% | 55.29 | 75.7% | $314.14m | |
| BIIB | Biogen, Inc. | 0.97% | 206.20 | 1.8% | $237.64m | |
| BNTX | BioNTech SE | 5.57% | 166.96 | 0.0% | $224.59m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | 2.38% | 2.15 | 0.7% | $150.29m | |
| EXAS | EXACT Sciences Corp. | 7.96% | 53.83 | 17.7% | $134.25m | |
| TECH | Bio-Techne Corp. | 5.81% | 386.56 | 4.5% | $107.96m | |
| TXG | 10X Genomics, Inc. | 11.91% | 52.99 | 0.0% | $106.79m | |
| BMRN | BioMarin Pharmaceutical, Inc. | 2.68% | 80.97 | 4.2% | $95.42m | |
| CRSP | CRISPR Therapeutics AG | 5.63% | 58.34 | 0.6% | $85.42m |
Company Profile
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.